Evolent Health, Inc. EVH
Regular-session close
After hours · Nov 20, 7:43 PM ET
- YTD
- -2.50%
- 1 year
- +5.69%
5D -0.99 (-20.25%)
- Market cap
- 441.11M
- Revenue (ttm)
- 2.20B
- Profit margin
- -5.94%
- EPS (ttm)
- -4.46
- Shares out
- 115.97M
- Forward P/E
- 6.01
- YTD return
- -2.50%
- 1-year return
- +5.69%
- 50-day average
- 9.86
- Volume
- 4.42M
- Avg volume
- 2.12M
- Open
- 3.44
- Previous close
- 3.43
- Day's range
- 3.45 – 4.16
- 52-week range
- 2.10 – 6.26
- Beta
- 0.73
- Analysts
- Strong Buy
- Price target
- 15.46 (+296.4%)
Key statistics
- 200-day average
- 9.96
- Enterprise value
- 1.98B
- Price / sales
- 0.45
- Price / book
- 1.11
- Revenue growth
- -31.30%
- Free cash flow
- -77.39M
- Total cash
- 151.00M
- Total debt
- 853.19M
- Return on equity
- -11.04%
- Short % of float
- 19.74%
Fundamental scorecard
6 of 25 checks passed on EVH’s reported financials
6of 25 checks passed
- Value 3 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 1, 2025 | 0.10 | — | — | — |
| Aug 7, 2025 | Jun 1, 2025 | 0.09 | — | -0.19 | -211.11% |
| May 8, 2025 | Mar 1, 2025 | 0.09 | 0.06 | -0.03 | -33.33% |
| Nov 7, 2024 | Sep 1, 2024 | 0.30 | 0.04 | -0.26 | -86.67% |
| Aug 8, 2024 | Jun 1, 2024 | 0.21 | 0.30 | +0.09 | +42.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2025 | Canaccord Genuity | main | Buy | Buy |
| Sep 9, 2025 | BTIG | reit | Buy | Buy |
| Aug 28, 2025 | Piper Sandler | main | Overweight | Overweight |
| Jul 17, 2025 | Truist Securities | main | Buy | Buy |
| Jun 20, 2025 | JMP Securities | reit | Market Outperform | Market Outperform |
| May 13, 2025 | Needham | reit | Buy | Buy |
About Evolent Health, Inc.
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated platform for health plan administration and value-based business infrastructure. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management; and Machinify Auth, a software platform that leverages advances in artificial intelligence. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- evolent.com
News
Gold Falls Sharply; US Consumer Sentiment Rises In November
12 Health Care Stocks Moving In Friday's Intraday Session
Buckle Posts Strong Q3 Results, Joins Evolent Health, Bending Spoons And Other Big Stocks Moving Higher On Friday Truist Securities Upgrades Evolent Health to Buy, Maintains Price Target to $6
Why Is Humana Stock Trading Higher Tuesday? Humana Partners With Evolent Health, American Oncology Network To Introduce New Cancel Care Model In 8 U.S. States
Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7
Needham Maintains Buy on Evolent Health, Raises Price Target to $6
Evolent Health Q3 2026 Earnings Call Transcript Evolent Health Affirms FY2026 Sales Guidance of $2.600B-$2.700B vs $2.626B Est
Your note
Sign in to keep a note on EVH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBAROSH CRAIG A | Director | Stock Award(Grant) | Jun 4, 2025 | 53,935 |
| BLACKLEY SETH | Chief Executive Officer | Stock Award(Grant) | Jun 30, 2025 | 829,367 |
| GRUA PETER J | Director | Stock Award(Grant) | Jun 4, 2025 | 82,647 |
| GUERTIN SHAWN M | Director | Stock Award(Grant) | Jun 4, 2025 | 21,979 |
| JELINEK RICHARD M | Director | Stock Award(Grant) | Jun 4, 2025 | 66,437 |
| JOHNSON JOHN PAUL | Chief Financial Officer | Stock Award(Grant) | Jun 30, 2025 | 309,245 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 9.29% | 10,921,531 | 93.93M | Jun 29, 2025 |
| Cadian Capital Management, LP | 8.87% | 10,424,701 | 89.65M | Jun 29, 2025 |
| Blackrock Inc. | 7.98% | 9,376,620 | 80.64M | Jun 29, 2025 |
| Morgan Stanley | 6.85% | 8,052,587 | 69.25M | Jun 29, 2025 |
| Durable Capital Partners Lp | 5.47% | 6,423,293 | 55.24M | Jun 29, 2025 |
| FMR, LLC | 5.46% | 6,420,384 | 55.22M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 5.77% | 6,778,267 | 58.29M | Apr 29, 2025 |
| Fidelity Securities Fund-Fidelity Small Cap Value Fund | 3.31% | 3,894,086 | 33.49M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.04% | 3,567,642 | 30.68M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.47% | 2,906,857 | 25.00M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.32% | 2,725,731 | 23.44M | Jun 29, 2025 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.76% | 2,070,815 | 17.81M | Jun 29, 2025 |
